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Background/Objective. It is known that menopause or lack of endogenous estrogen is a risk factor for endothelial dysfunction and
CAD. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is involved inmultiple phases of vascular dysfunction.The
purposeofthecurrentstudywastodeterminetheassociationbetweensolubleLOX-1(sLOX-1)andpregnancyfollowedbydelivery
i nw o m e no fr e p r o d u c t i v ea g e .Materials/Methods. Sixty-eight subjects with pregnancy followed by delivery (group 1) and 57
subjects with nongravidity (group 2) were included in this study. Levels of sLOX-1 were measured in serum by EL SA. Results.
Plasma levels of sLOX-1 were signiﬁcantly lower in Group 1 than Group 2 in women of reproductive age (0.52 ± 0.18ng/mL and
0.78 ± 0.13, resp., P<0.001). There were strong correlations between sLOX-1 levels and the number of gravida (r =− 0.645,
P<0.001). The levels of sLOX-1 highly correlated with the number of parous (r =− 0.683, P<0.001). Conclusion.O u r
study demonstrated that serum sLOX-1 levels were associated with pregnancy followed by delivery that might predict endothelial
dysfunction. We conclude that pregnancy followed by delivery may delay the beginning and progress of arteriosclerosis and its
clinical manifestations in women of reproductive age.
1.Introduction
Even though substantial eﬀorts have been made to improve
education and public awareness and despite the use of
eﬀective medications and life-style changes for controlling
the associated risk factors, coronary artery disease (CAD)
remains the leading cause of death in women worldwide
[1, 2]. In contrast to age-matched men, the incidence of
clinical manifestations of CAD is considerably lower in pre-
menopausal women; however, most of women develop CAD
after menopause when endogenous estrogen levels are low
[3–5].
During normal menstrual cycles, women show high
levels of estrogen just before ovulation and during the luteal
phase and in the normal physiology of pregnancy, women
have signiﬁcantly higher levels of estrogen derived mainly
from the placenta [6]. Estrogens have been known to exert
various positive eﬀects on the cardiovascular system [7, 8].
It has thus been shown that estrogens retard the atheroscle-
rotic process and induce rapid vasodilatation through the
production of an endothelium-derived vasoactive mediator,
nitricoxide(NO)[8–10].Hashimotoetal.[11]reportedthat
endothelium-dependent vasodilatation is increased in young
women during the phases of their menstrual cycles when
endogenous estrogen levels are high, and pregnant women
show signiﬁcantly high levels of estrogen. Some studies have
documented that estrogens are potent antioxidants and
decrease low-density lipoprotein cholesterol (LDL-C) oxida-
tion in vitro and in vivo [12, 13]. While estrogens decrease
lipid peroxidation and formation of reactive oxygen species
[14], androgens and progestins increase oxidative stress
parameters [15].
Lectin-like oxidized low-density lipoprotein receptor-1
(LOX-1), a type II membrane glycoprotein, is the major
receptor for oxidized low-density lipoprotein (ox-LDL) in
endothelial cells [16]. Oxidative stress and ox-LDL both alter2 Mediators of Inﬂammation
endothelial biology by activating a speciﬁc receptor LOX-1.
The activation of LOX-1 has been shown to lead to further
oxidative stress in endothelial cells and the appearance of
proinﬂammatory phenotype [17]. LOX-1, furthermore, is
cleaved at the membrane-proximal extracellular domain by
proteases [18, 19] that may also be associated with endothe-
lial dysfunction and atherosclerotic plaque formation and
destabilization, resulting in soluble LOX-1 (sLOX-1) release
into the circulation [19]. Since the level of soluble receptors
in circulating blood may reﬂect the expression of membrane
proteins and disease activities, sLOX-1 may be a potential
biomarker of vascular disease assessment.
Therefore, we hypothesized that if women have been
exposed for a longer time and/or at a higher level to
endogenous (not exogenous) estrogen, such as pregnancy
followed by delivery and/or gravidity, they may obtain
estrogen’s beneﬁcial “cardioprotective,” “antiatherosclerosis,”
and/or “antioxidant” eﬀect. The purpose of the current
study was to determine the association between pregnancy
followed by delivery and sLOX-1.
2. Methods
2.1. Patient Population. From January 2010 to June 2011, we
prospectively evaluated 1284 patients in cardiology outpa-
tient clinic of our hospital. Sixty-eight subjects with preg-
nancy followed by delivery (Group 1) and 57 subjects with
nongravidity (Group 2) were included in this study. All par-
ticipants provided written informed consent to participate
in the study. The protocol was approved by the local Ethics
Committee.
Exclusion criteria included pregnancy, known polycystic
ovary syndrome, congestive heart failure (ejection fraction
<50%), myocardial infarction, stroke, known peripheral
atherosclerotic disease, surgical coronary intervention, other
major vascular surgical procedures, coronary angioplasty,
unstable angina pectoris, diabetes mellitus, hypertension,
suspected myocarditis or pericarditis, impaired renal func-
tion (creatinine ≥1.4mg/dL), unstable endocrine or meta-
bolic diseases known to inﬂuence serum inﬂammation
markers, concomitant inﬂammatory diseases such as infec-
tions and autoimmune disorders, active or chronic hepatic/
hepatobiliary disease, and malignancy. Patients taking oral
contraceptive, corticosteroids, anti-oxidant vitamins, and
alcohol were also excluded from the study.
2.2. Blood Sampling and Laboratory Methods. Blood samples
of all individuals were taken from an antecubital vein fol-
lowing an overnight fasting state at the ﬁrst three days of me-
narche. After centrifugation at 3000×gf o r1 0m i n u t e s ,
serum and plasma samples were frozen and stored at −80◦C
until an assay could be performed. Serum sLOX-1 levels were
measured by a commercially available enzyme-linked im-
munosorbent assay kit (USCN Life Science, Wuhan, China).
The detection limit for serum sLOX-1 level was 2.4pg/mL
with a coeﬃcient of variation <5%. Triglyceride (TG), total
cholesterol (tot-C), LDL-C, and high-density lipoprotein
cholesterol (HDL-C) concentrations were measured by
automated chemistry analyzer (Roche Diagnostics, Indian-
apolis, USA) by using commercially available kits.
3.StatisticalAnalysis
Continuous variables were given as mean ± SD; categorical
variables were deﬁned as percentages. Comparisons between
Group-1andGroup-2werecarriedoutusinganindependent
samples t-test. Correlation analyses were performed using
the Pearson coeﬃcient of correlation. SPSS 15.0 software was
used for basic statistical analysis (Version 15, SPSS Inc., and
Chicago, IL, USA). A value of P<0.05 was accepted as sta-
tistically signiﬁcant.
4. Result
The clinical and demographic characteristics of study sub-
jects were summarized in Table 1. The mean age was 33.5 ±
6.1 years in pregnancy followed by delivery group and 35.5±
7.5 years in nongravidity group (P = 0.1). The mean age of
ﬁrst menarche was 12.1 ± 2.3 years in pregnancy followed
by delivery group and 11.9±1.9 years in nongravidity group
(P = 0.5). The rates of family history and smoke were similar
between the two groups (Table 1). The smoker subjects in
G r o u p1h a d3 .5 ± 1.3 pack-year history of smoking, and
smoker subjects in Group 2 had 5.0 ± 2.1 pack-year history
of smoking (P = 0.1). The levels of total-C, LDL-C, HDL-
C, and triglyceride were also similar between the two groups
(Table 1).
Figure 1 shows the sLOX-1 levels between two groups.
The sLOX-1 levels were signiﬁcantly higher in nongravidity
group than pregnancy followed by delivery group (0.78 ±
0.13ng/mL and 0.52 ± 0.18ng/mL, resp., P<0.001). The
sLOX-1 levels highly negatively correlated with the number
of gravida (Figure 2, r =− 0.645, P<0.001). Figure 3
shows a highly negative correlation between sLOX-1 levels
and number of parous (r =− 0.683, P<0.001). The sLOX-1
levels were not correlated with age and age of ﬁrst menarche
(r = 0.055, P = 0.541 and r =− 0.015, P = 0.865, resp.).
In the multiple linear regression analysis age was positively
related and number of gravity was negatively related with
sLOX-1 levels (for age P = 0.011, beta = 0.169, t = 2,589
for parous P<0.001, beta =− 0.713, t =− 10,912).
5. Discussion
To the best of our knowledge, this is the ﬁrst study that
shows the relationship between sLOX-1 levels and pregnancy
followed by delivery in women of reproductive age. This
study showed that women who had at least 1 pregnancy
followed by delivery showed a decreased level of sLOX-1
compared with those who had never experienced delivery.
The sLOX-1 levels had signiﬁcantly negative correlation with
gravida and parous. We hypothesized that if women have
been exposed for a longer time and/or at a higher level to
endogenous (not exogenous) estrogen, such as pregnancy
followed by delivery and/or gravidity, they may obtain
estrogen’s beneﬁcial eﬀect and may have a greater decrease
in level of sLOX-1. These ﬁndings may support the idea thatMediators of Inﬂammation 3
Table 1: The clinical and demographic characteristics of study subjects.
Group 1 ( n = 68) Group 2 (n = 57) P value
Age (years) 33.5 ±6.13 5 .5 ±7.50 . 1
Age of menarche (years) 12.1 ±2.31 1 .9 ±1.90 . 5
Smoke (%) 11.8% 15.8% 0.6
Family history (%) 7.4% 5.3% 0.7
Lipid proﬁle (mg/dL)
Total-C 179 ±39 183 ±28 0.4
LDL-C 108 ±31 113 ±23 0.3
HDL-C 45 ±12 45 ±11 0.7
Triglycerides 120 ±66 132 ±58 0.3
Data expressed as mean ± SD or percentage. P<0.05 was accepted as statistically signiﬁcant. Total-C: total cholesterol, LDL-C: low-density lipoprotein
cholesterol, HDL-C: high-density lipoprotein cholesterol. Group 1: pregnancy followed by delivery group, Group 2: nongravidity group.
as long as women are exposed to endogenous estrogen they
have decreased level of sLOX-1.
Coronary artery disease remains the leading cause of
death in the 21st century. Despite the advances in this area, it
is still the main cause of death among women in developed
countries [20]. The prevalence of CAD in premenopausal
women is smaller than in postmenopausal women, when
there is an exponential increase, making the risk for women
equal to that for men by the age of 65–70 years. This lag
concerning the age period at which the frequency of cardio-
vascular events increases among women as compared to men
has been ascribed to the actions of endogenous estrogen on
the cardiovascular system, through mechanisms as yet not
completely clariﬁed.
The well-known risks for CAD, such as systemic hyper-
tension, smoking, obesity, sedentary life-style, dyslipidemia,
stress, family history of CAD, diabetes mellitus, menopause,
lack of endogenous estrogen, and insulin resistance, are nu-
merous[21].Morerecently,endothelialvasculardysfunction
has become suspected as being associated with CAD. The
term endothelial dysfunction is more frequently used to re-
fering reduction in endothelium-dependent vasodilatation,
associated with diminished bioactivity of local vasodilative
factors (especially NO). Data from prospective trials have
been conﬁrming the hypothesis that endothelial dysfunction
precedes the emergence of chronic disorders. Currently, it is
a consensus that endothelial dysfunction is the initial event
in development of atherosclerosis [22]. There are many tech-
niques for investigating the endothelial function, from those
that focus on cellular and molecular aspects, through meth-
ods involving tissue culture and molecular biology tools, to
clinical trials applied to human beings, using invasive and
noninvasive procedures to evaluate endothelium-dependent
vasodilatation, or the determination of plasmatic substances
that indicate endothelial activation and/or damage.
The incidence of CAD and mortality is very low in
women of reproductive age but rises to a signiﬁcant level in
menopause women [23] .T h e r ei se v i d e n c eo fa na s s o c i a t i o n
between endothelial dysfunction and reduced endogenous
p r o d u c t i o no fe s t r o g e n sa f t e rn a t u r a lo rs u r g i c a lm e n o p a u s e
or premature ovarian failure in women with or without
CAD [24–27]. The actions of endogenous estrogens on the
cardiovascular system can be mediated directly on the vessels
or indirectly through the modulation of cardiovascular risk
factors, as well as on the lipid proﬁle [28]. The direct eﬀects
of estrogen on the vascular system and which modulate the
vasculartonus comprise the following 1 acute vasodilatation,
increasing the synthesis and bioactivity of NO [29, 30];
2 long-term modulation of vascular tonus, regulating the
production of prostaglandins and expression of endothelial
nitric oxide synthase and the endothelin gene [31]; 3
inhibition of endothelin-induced vasoconstriction [32]; and
4 inhibition of sympathetic activity [24]. In addition to these
actions on the vascular tonus, estrogen exerts an antipro-
liferative action on the vascular smooth layer [33]. Also, it
appears to have a major role in vascular remodeling, inhibit-
ing the proliferation of the inner layer after injury [34]a n d
increasing the expression of contractile proteins in the myo-
cardium [35].
Disturbances in endothelial function have an important
role in the physiopathology of atherosclerosis, and several
lines of evidence suggest that interventions in endothelial
function could modify the progress rates of atherosclerotic
disease and the risk of cardiovascular events. Some studies
have documented that estrogens are potent antioxidants and
decrease LDL-C oxidation in vitro and in vivo [12, 13].
Studies on the mechanism of estrogen antioxidant eﬀects
haveshownthatestrogenstronglyinhibitssuperoxideforma-
tion with minor eﬀects on hydrogen peroxide and hydroxyl
radical formation [14]. While estrogen decreases lipid per-
oxidation and formation of reactive oxygen species, [14]
androgens and progestins increase oxidative stress parame-
ters [15]. Clinical studies on humans using 17β-estradiol-
based preparations have clearly shown decreased LDL-C
oxidation, and in addition, estradiol reduces the develop-
ment of early lesions of atherosclerosis, in part through
the eﬀects on lipid metabolism which reduce lipid deposits
in the endothelium [36, 37].
Cevic et al. demonstrated that a high concentration of
estrogen reduces the level of asymmetric dimethylarginine
(ADMA), which is an endogenous competitive inhibitor of
NO synthase [38]. Estradiol, by reducing ADMA, may there-
fore facilitate NO synthesis in endothelial cells. Hashimoto
et al. [39] also demonstrated that women who had had at4 Mediators of Inﬂammation
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Figure 1: The comparison of sLOX-1 levels between two groups
(Group 1: pregnancy followed by delivery group, Group 2: non-
gravidity group. Soluble LOX-1 levels were 0.78 ± 0.13ng/mL in
nongravidity group and 0.52 ± 0.18ng/mL in pregnancy followed
by delivery group, P<0.001).
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Figure 2: The correlation between sLOX-1 levels and number of
gravida.
least 1 pregnancy followed by delivery showed a decreased
level of arteriosclerosis, measured noninvasively by brachial-
ankle pulse wave velocity (ba-PWV) as an indicator of
arteriosclerosis. It was closely correlated with aortic arterial
stiﬀness and the severity of atherosclerosis, compared with
those who had never experienced delivery. Human umbilical
vein endothelial cells exposed to high concentration of 17β-
estradiol were used as an antiatherosclerogenic agent to
demonstrate feasibility in an in vitro vascular model [40].
LOX-1, a type II membrane glycoprotein, is the major
receptor for ox-LDL in endothelial cells [16]. It is also
expressed by macrophages and vascular smooth muscle cells
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Figure 3: The correlation between sLOX-1 levels and number of
parous.
[41].Oxidativestressandox-LDLbothalterendothelialbiol-
ogy by activating a speciﬁc receptor LOX-1. The activation
of LOX-1 has been shown to lead to further oxidative stress
in endothelial cells and the appearance of proinﬂammatory
phenotype [17]. LOX-1 has been implicated in vascular
inﬂammation and atherosclerotic plaque formation, pro-
gression, and destabilization [42, 43]. LOX-1, furthermore,
is cleaved at the membrane-proximal extracellular domain
by proteases, including a disintegrin and matrix metallopro-
teinases (MMPs) [18, 19] that may also be associated with
plaque vulnerability or rupture, resulting in soluble LOX-
1 (sLOX-1) release into the circulation [19]. In addition,
plasma sLOX-1 levels were higher in males and smokers than
in females and nonsmokers, probably because endogenous
estrogen and smoking aﬀect plaque vulnerability by protect-
ing vascular cells from inﬂammation (the former) [8]a n d
by inducing oxidative stress and inﬂammation (the latter)
[44]. In experimental animal models, LOX-1 expression is
closely associated with morphological plaque instability and
cell apoptosis, as well as with the expression of MMPs and
tissue factor, all of which are associated with plaque rupture
and thrombus formation [45–47]. A study demonstrated
that LOX-1 deﬁciency signiﬁcantly decreases the formation
of atherosclerotic lesions and endothelial dysfunction [48].
It is well known that menopause or lack of endogenous
estrogen is a risk factor for cardiovascular disease [49–51].
Hashimotoetal.[39]reportedthatwomenwhoareregularly
menstruating have a decreased PWV compared with post-
menopausal women of the same age and a younger age
at menarche correlates with PWV reduction. This ﬁnding
may support the idea that as long as women are exposed
to endogenous estrogen they have decreased endothelial
dysfunction. Cardiovascular risk increases after bilateral
ovariectomy and in conditions associated with impaired
ovarian function. Thus, ovarian dysfunction and either nat-
ural or surgical menopause have been recognized as a major
risk factor for accelerated atherosclerotic vascular disease
development[3,52].Instagesofdisruptedovulatorycycling,Mediators of Inﬂammation 5
low levels of endogenous oestrogens during premenopausal
years accelerate the progression of atherosclerosis [53, 54],
which can be reversed by oestrogen therapy in animals [53].
In addition, results from experimental studies and recent
clinical trials indicate that oestrogen therapy started within
few years after menopause, that is, before the development
of severe atherosclerosis, may in fact reduce cardiovascular
risk [5, 55–59]. In contrast, initiation of oestrogen therapy
many years after menopause, that is, when advanced and
multiple atherosclerotic lesions are present, may have no or
even deleterious cardiovascular eﬀects [5, 55–59].
Inconclusion,ourstudydemonstratedthatserumsLOX-
1 levels were associated with pregnancy followed by delivery
which might predict endothelial dysfunction. Pregnancy
followed by delivery may improve endothelial function and
prevent the progress of atherosclerosis in women of repro-
ductive age. LOX-1 can be used as a target for imaging of
endothelial function. We conclude that pregnancy followed
by delivery may delay the progress of arteriosclerosis and its
clinical manifestations in women of reproductive age.
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